{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:31:55Z","timestamp":1788294715144,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ekir.2023.10.008","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T04:06:26Z","timestamp":1697601986000},"page":"39-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Systematic Review of Cardiovascular Benefits and Safety of Sacubitril-Valsartan in End-Stage Kidney Disease"],"prefix":"10.1016","volume":"9","author":[{"given":"Mariam","family":"Charkviani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pajaree","family":"Krisanapan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charat","family":"Thongprayoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iasmina M.","family":"Craici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wisit","family":"Cheungpasitporn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2023.10.008_bib2","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ki.2011.223","article-title":"Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: improving Global Outcomes (KDIGO)","volume":"80","author":"Herzog","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.10.008_bib3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00000441-200304000-00004","article-title":"Congestive heart failure in patients with chronic kidney disease and on dialysis","volume":"325","author":"Schreiber","year":"2003","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.ekir.2023.10.008_bib4","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1053\/ajkd.2001.28588","article-title":"A\u00a0cross-sectional study of the prevalence and clinical correlates of congestive heart failure among incident US dialysis patients","volume":"38","author":"Stack","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2023.10.008_bib5","article-title":"Diagnosis and management of cardiovascular disease in advanced and end-stage renal disease","volume":"5","author":"Bhatti","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.ekir.2023.10.008_bib6","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1161\/01.CIR.90.6.2786","article-title":"Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade","volume":"90","author":"London","year":"1994","journal-title":"Circulation"},{"issue":"Suppl 3","key":"10.1016\/j.ekir.2023.10.008_bib7","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1053\/ajkd.1998.v32.pm9820470","article-title":"Clinical epidemiology of cardiovascular disease in chronic renal disease","volume":"32","author":"Foley","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2023.10.008_bib8","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrneph.2009.156","article-title":"Mechanisms of the cardiorenal syndromes","volume":"5","author":"Shamseddin","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2023.10.008_bib9","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1053\/j.ajkd.2016.12.006","article-title":"Sudden cardiac death among hemodialysis patients","volume":"69","author":"Makar","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2023.10.008_bib10","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1681\/ASN.2009121210","article-title":"Rate of kidney function decline associates with mortality","volume":"21","author":"Al-Aly","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.10.008_bib12","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.ijcard.2012.10.007","article-title":"The past, present and future of renin-angiotensin aldosterone system inhibition","volume":"167","author":"Mentz","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ekir.2023.10.008_bib13","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/ehf2.12659","article-title":"Sacubitril\/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease","volume":"7","author":"Lee","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.ekir.2023.10.008_bib14","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.10.008_bib15","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMp1410241","article-title":"Paradigm shifts in heart-failure therapy\u2014a timeline","volume":"371","author":"Sacks","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.10.008_bib16","first-page":"e240","article-title":"ACCF\/AHA guideline for the management of heart failure","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2023.10.008_bib17","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ekir.2023.10.008_bib18","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ekir.2023.10.008_bib19","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary","volume":"79","author":"Heidenreich Paul","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ekir.2023.10.008_bib20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ekir.2023.10.008_bib21","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.ekir.2023.10.008_bib22","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0895-4356(92)90054-Q","article-title":"Variance imputation for overviews of clinical trials with continuous response","volume":"45","author":"Follmann","year":"1992","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.ekir.2023.10.008_bib23","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1002\/sim.2423","article-title":"Meta-analysis of heterogeneously reported trials assessing change from baseline","volume":"24","author":"Abrams","year":"2005","journal-title":"Stat Med"},{"key":"10.1016\/j.ekir.2023.10.008_bib24","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"Robins-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ekir.2023.10.008_bib25","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.ekir.2023.10.008_bib26","article-title":"Sacubitril\/Valsartan in patients with heart failure and concomitant end-Stage kidney disease","volume":"11","author":"Niu","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.ekir.2023.10.008_bib27","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000519643","article-title":"Pharmacokinetics and pharmacodynamics of Sacubitril\/Valsartan in maintenance hemodialysis patients with heart failure","volume":"51","author":"Feng","year":"2022","journal-title":"Blood Purif"},{"key":"10.1016\/j.ekir.2023.10.008_bib28","article-title":"Effects of Sacubitril-Valsartan in heart failure with preserved ejection fraction in patients undergoing peritoneal dialysis","volume":"8","author":"Fu","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ekir.2023.10.008_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.955780","article-title":"Effects of sacubitril\/valsartan in ESRD patients undergoing hemodialysis with HFpEF","volume":"9","author":"Guo","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ekir.2023.10.008_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.794707","article-title":"Angiotensin receptor-neprilysin inhibitors in patients with heart failure with reduced ejection fraction and advanced chronic kidney disease: a retrospective multi-institutional study","volume":"9","author":"Hsiao","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ekir.2023.10.008_bib31","first-page":"117","article-title":"Efficacy of sacubitril\/valsartan in peritoneal dialysis patients with HFpEF and its effect on residual renal function","volume":"103","author":"Ma","year":"2023","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.ekir.2023.10.008_bib32","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/jch.14422","article-title":"Effects of Sacubitril\/Valsartan on resistant hypertension and myocardial work in hemodialysis patients","volume":"24","author":"Wang","year":"2022","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.ekir.2023.10.008_bib33","first-page":"288","article-title":"Use of angiotensin receptor neprilysin inhibitor in patients on maintenance hemodialysis with reduced cardiac ejection fraction, real-world experience from a Single Center","volume":"15","author":"Lihua","year":"2021","journal-title":"Iran J Kidney Dis"},{"key":"10.1016\/j.ekir.2023.10.008_bib34","first-page":"3439","article-title":"Effects and safety of Sacubitril\/Valsartan (SV) on heart function and blood pressure in maintenance hemodialysis (MHD) patients","volume":"14","author":"Wen","year":"2022","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.ekir.2023.10.008_bib35","article-title":"Sacubitril-Valsartan increases ultrafiltration in patients undergoing peritoneal dialysis: a short-term retrospective self-controlled study","volume":"9","author":"Zhang","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ekir.2023.10.008_bib36","article-title":"The efficacy and safety of Sacubitril\/Valsartan on pulmonary hypertension in hemodialysis patients","volume":"9","author":"Zhao","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ekir.2023.10.008_bib37","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.10.008_bib38","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1523-1755.2005.00079.x","article-title":"B-type natriuretic peptide for acute dyspnea in patients with kidney disease: insights from a randomized comparison","volume":"67","author":"Mueller","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.10.008_bib39","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.10.008_bib40","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ejhf.1498","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ekir.2023.10.008_bib41","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/ejhf.603","article-title":"Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis","volume":"18","author":"Solomon","year":"2016","journal-title":"Eur J Heart Fail"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024923015395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024923015395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:46:20Z","timestamp":1762832780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024923015395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2468024923015395"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2023.10.008","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic Review of Cardiovascular Benefits and Safety of Sacubitril-Valsartan in End-Stage Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2023.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2023.11.015","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}